UNCY News

Investors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before November 2, 2026

UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Investor Alert: Deadline Approaching to Join Unicycive Therapeutics, Inc. (UNCY) Class Action – Contact Levi & Korsinsky

Join Class Action to Recover Losses From Unicycive Therapeutics, Inc. (UNCY) - Contact Levi & Korsinsky Before November 2, 2026

Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal Rights

Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

Securities Fraud Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - Levi & Korsinsky Reminds Investors of November 2, 2026

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm

Class Action Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of November 2, 2026 Deadline